Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.46 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.46 |
| ▸ | PIK3R5 | Q8WYR1 | 2/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3780652 | 0.90 | SMN1; SMN2 (1.00) | SMN1; SMN2ALDH1A1PDE10AHIF1AHPGD | |
| SCHEMBL2726410 | 0.79 | SMN1; SMN2 (0.60) | SMN1; SMN2ALDH1A1HPGDMAPK1PIK3CA | |
| SCHEMBL16167417 | 0.78 | SMN1; SMN2 (0.62) | SMN1; SMN2ALDH1A1PDE10AHIF1AHPGD | |
| SCHEMBL30455285 | 0.78 | SMN1; SMN2 (0.97) | SMN1; SMN2ALDH1A1ACHEEHMT2KDM4E | |
| SCHEMBL4092118 | 0.78 | SMN1; SMN2 (0.97) | SMN1; SMN2ALDH1A1ACHEEHMT2KDM4E | |
| SCHEMBL3318391 | 0.77 | SMN1; SMN2 (1.00) | SMN1; SMN2ALDH1A1ACHEEHMT2KDM4E | |
| SCHEMBL2726311 | 0.76 | SMN1; SMN2 (0.59) | SMN1; SMN2ALDH1A1HPGDMAPK1PIK3CA | |
| SCHEMBL4113454 | 0.76 | SMN1; SMN2 (0.59) | SMN1; SMN2ALDH1A1PDE10AHPGDCYP1A2 | |
| SCHEMBL16167232 | 0.74 | SMN1; SMN2 (0.44) | SMN1; SMN2ALDH1A1EHMT2KDM4E | |
| SCHEMBL18421140 | 0.73 | SMN1; SMN2 (0.53) | SMN1; SMN2ALDH1A1PDE10AHPGDCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210113578-A1 | QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS | ASANA BIOSCIENCES, LLC | 2021-04-22 | — | — | US | disclosed |
| US-10912779-B2 | Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways | ASANA BIOSCIENCES, LLC (US) | 2021-02-09 | — | — | US | disclosed |
| US-10869872-B2 | — | — | 2020-12-22 | — | — | US | disclosed |
| US-20190151327-A1 | QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS | ASANA BIOSCIENCES, LLC | 2019-05-23 | — | — | US | disclosed |
| EP-2984088-B1 | QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS | ASANA BIOSCIENCES LLC (US) | 2019-03-20 | — | — | EP | disclosed |
| US-10226468-B2 | Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways | ASANA BIOSCIENCES, LLC (US) | 2019-03-12 | — | — | US | disclosed |
| US-20170290838-A1 | QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS | ASANA BIOSCIENCES, LLC | 2017-10-12 | — | — | US | disclosed |
| US-20170290838-A1 | QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS | ASANA BIOSCIENCES, LLC | 2017-10-12 | — | — | US | disclosed |
| US-9757382-B2 | Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways | ASANA BIOSCIENCES, LLC (US) | 2017-09-12 | — | — | US | disclosed |
| US-9757382-B2 | Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways | ASANA BIOSCIENCES, LLC (US) | 2017-09-12 | — | — | US | disclosed |
| US-20170027953-A1 | QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2017-02-02 | — | — | US | disclosed |
| US-20170027953-A1 | QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2017-02-02 | — | — | US | disclosed |
| US-9499495-B2 | Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways | ASANA BIOSCIENCES, LLC (US) | 2016-11-22 | — | — | US | disclosed |
| US-9499495-B2 | Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways | ASANA BIOSCIENCES, LLC (US) | 2016-11-22 | — | — | US | disclosed |
| US-20160068496-A1 | QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160068496-A1 | QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2016-03-10 | — | — | US | disclosed |
| WO-2014169167-A1 | QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2014-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068496-A1 | QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS | NRAS, KRAS, BRAF | SMN1; SMN2 2454/4885ALDH1A1 3747/4885PDE10A 1133/4885 |
| US-20190151327-A1 | QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS | NRAS, KRAS, BRAF | SMN1; SMN2 2448/4885ALDH1A1 3815/4885PDE10A 1142/4885 |
| US-20170290838-A1 | QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS | NRAS, KRAS, BRAF | SMN1; SMN2 2448/4885ALDH1A1 3815/4885PDE10A 1142/4885 |
| US-10869872-B2 | — | NRAS, KRAS, BRAF | SMN1; SMN2 1478/4885ALDH1A1 3639/4885PDE10A 645/4885 |
| US-20170027953-A1 | QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS | NRAS, KRAS, BRAF | SMN1; SMN2 2448/4885ALDH1A1 3815/4885PDE10A 1142/4885 |
| US-10226468-B2 | Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways | NRAS, KRAS, BRAF | SMN1; SMN2 2448/4885ALDH1A1 3815/4885PDE10A 1142/4885 |
| US-20210113578-A1 | QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS | NRAS, KRAS, BRAF | SMN1; SMN2 2448/4885ALDH1A1 3815/4885PDE10A 1142/4885 |
| US-10912779-B2 | Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways | NRAS, KRAS, BRAF | SMN1; SMN2 2448/4885ALDH1A1 3815/4885PDE10A 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.